Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk - A systematic review and meta-analysis

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Schiffner Rohe, Julia ^a   Witt, Annika ^b   Hemmerling, Jana ^b   Von Eiff, Christof ^a   Leverkus, Friedrich Wilhelm ^a  

^a PFIZER INC   (United States)

^b Advanced Medical Services   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23 VALENT; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

ADULT; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; PNEUMOCOCCAL COMMUNITY ACQUIRED PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SELECTION BIAS; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VACCINATION; VALIDITY; AGED; CLINICAL TRIAL (TOPIC); COMMUNITY-ACQUIRED INFECTIONS; FEMALE; IMMUNOLOGY; MALE; META ANALYSIS; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; RISK FACTOR; STATISTICAL BIAS;

ADULT; AGED; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; TREATMENT OUTCOME;

EID: 84955438517     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146338     Document Type: Article

References (34)

1. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2013; 32(3):305-16. doi: 10.1007/s10096-012-1778-4 PMID: 23242464
2. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014; 33(7):1065-79. doi: 10.1007/s10096-014-2067-1 PMID: 24532008
3. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012; 67(1):71-9. doi: 10.1136/thx.2009.129502 PMID: 20729232
4. Cilloniz C, Polverino E, Ewig S, Aliberti S, Gabarrus A, Menendez R, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest. 2013; 144(3):999-1007. doi: 10.1378/chest.13-0062 PMID: 23670047
5. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a metaanalysis. CMAJ. 2009; 180(1):48-58. doi: 10.1503/cmaj.080734 PMID: 19124790
6. Sicras-Mainar A, Ibanez-Nolla J, Cifuentes I, Guijarro P, Navarro-Artieda R, Aguilar L. Retrospective epidemiological study for the characterization of community-acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain). BMC Infect Dis. 2012; 12:283. doi: 10.1186/1471-2334-12-283 PMID: 23114195
7. van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012; 65 (1):17-24. doi: 10.1016/j.jinf.2012.02.017 PMID: 22394683
8. Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther. 2014; 31(10):1011-44. Epub 2014/10/11. doi: 10.1007/s12325-014-0157-1 PMID: 25300593
9. Robert Koch-Institut. Epidemiologisches Bulletin Nr. 34. Mitteilung der Ständigen Impfkommission am Robert Koch-Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2014. 2014. Verfügbar unter: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2014/Ausgaben/34-14.pdf?-blob=publicationFile.
10. European Medicines Agency (EMA). Assessment report: Prevenar 13 (EMEA/H/C/001104/II/0028). 2011.
11. Advisory Commitee on Immunization Practices (ACIP). Summary Report-August 13, 2014. 2014. Verfügbar unter: http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2014-08.pdf.
12. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013; 1:CD000422. Epub 02/27. doi: 10.1002/14651858. CD000422.pub3 PMID: 23440780
13. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012; 30(48):6802-8. doi: 10.1016/j.vaccine.2012.09.019 PMID: 23000122
14. Salisbury CB. JCVI advice on the pneumococcal vaccination programme for people aged 65 years and older. 2011. Verfügbar unter: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/215686/dh-125244.pdf.
15. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee Immunization Practices (ACIP). Morbidity and Mortality Weekly ReportMorbidity and Mortality Weekly Report. 2014; 63(37):822-5.
16. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372(12):1114-25. doi: 10.1056/NEJMoa1408544 PMID: 25785969
17. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011. Verfügbar unter: http://handbook.cochrane.org/chapter-16/16-9-2-studies-with-zero-cell-counts.htm. [Zugriffsdatum: 13.10.2015].
18. a-Version 4.2. 2015.
19. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al. Clinical efficacy of antipneumococcal vaccination in patients with COPD. Thorax. 2006; 61(3):189-95. PMID: 16227328
20. Furumoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008; 26(33):4284-9. doi: 10.1016/j.vaccine.2008.05.037 PMID: 18585831
21. Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010; 28(43):7063-9. doi: 10.1016/j.vaccine.2010.08.010 PMID: 20723631
22. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010; 340:c1004. doi: 10.1136/bmj. c1004 PMID: 20211953
23. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Läärä E, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999; 17:2493-500. PMID: 10418894
24. Örtqvist Å, Hedlund J, Burman L-Å, Elbel E, Höfer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. The Lancet. 1998; 351(9100):399-403.
25. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, Andreo F, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013; 8(4):e60273. Epub 2013/04/09. doi: 10.1371/journal.pone.0060273 PMID: 23565216
26. Liapikou A, Polverino E, Cilloniz C, Peyrani P, Ramirez J, Menendez R, et al. A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia. Respir Care. 2014; 59(7):1078-85. Epub 2013/11/07. doi: 10.4187/respcare.02788 PMID: 24194575
27. Dowell SFGRLLGLOSYY-H. Evaluation of Binax NOW, an Assay for the Detection of Pneumococcal Antigen in Urine Samples, Performed among Pediatric Patients. Clinical Infectious Diseases. 2001; 32:824-5. PMID: 11229853
28. Hamer DHE, J.; Estrella B.; MacLeod W.B.; Griffiths J.K.; Sempertegui F. Assessment of the Binax NOW Streptococcus pneumoniae Urinary Antigen Test in Children with Nasopharyngeal Pneumococcal Carriage. Clinical Infectious Diseases. 2002; 34:1025-8. PMID: 11880971
29. Horita N, Miyazawa N, Kojima R, Kimura N, Inoue M, Ishigatsubo Y, et al. Sensitivity and specificity of the Streptococcus pneumoniae urinary antigen test for unconcentrated urine from adult patients with pneumonia: a meta-analysis. Respirology. 2013; 18(8):1177-83. doi: 10.1111/resp.12163 PMID: 23910720
30. Jalonen EP, J.C.; Koskela M.; Kerttula Y.; Leinonen M. Measurement of antibody responses to pneumolysin-a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. Journal of Infection. 1989; 19:127-34. PMID: 2809235
31. Leinonen M, Syrjälä H, Jalonen E, Kujala P, Herva E. Demonstration of pneumolysin antibodies in circulating immune complexes-a new diagnostic method for pneumococcal pneumonia. Serodiagn Immonuther Infect Dis. 1990; 4:451-8.
32. Scott JAGH, A.J.; Leinonen M. Validation of Immune-Complex Enzyme Immunoassays for Diagnosis of Pneumococcal Pneumonia among Adults in Kenya. Clinical and Diagnostic Laboratory Immunology. 2000:64-7. PMID: 10618279
33. Musher DMM, R.; Phan H.M.; Chen G,; Baughn R.E. Nonspecificity of Assaying for IgG Antibody to Pneumolysin in Circulating Immune Complexes as a Means to Diagnose Pneumococcal Pneumonia. Clinical Infectious Diseases. 2001; 32:534-8. PMID: 11181114
34. Paton JCL, R.A.; Lee C-J.; Li J.P; Berry A.M; Mitchell T.J.; Andrew P.W.; Hansman D.; Boulnois G.J. Purification and Immunogenicity of Genetically Obtained Pneumolysin Toxoids and Their Conjugation to Streptococcus pneumoniae Type 19F Polysaccharide Infection and Immunity. 1991:2297-304. PMID: 2050399